1-6 of 6
Johannes Oldenburg
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU

Clinical Trials & Observations
Kathelijn Fischer, Gili Kenet, Karin Kurnik, Manuel Carcao, Johannes Oldenburg, Torben Stamm-Mikkelsen, Ana Rosa Cid Haro, Minna Koskenvuo, Jan Blatny, Christoph Königs
Journal: Blood Advances
Blood Adv (2024) 8 (2): 369–377.
https://doi.org/10.1182/bloodadvances.2023011442
Published: 2024
Includes: Supplemental data
Journal Articles

Post hoc longitudinal assessment of the efficacy and safety of recombinant factor IX Fc fusion protein in hemophilia B

Clinical Trials & Observations
Amy D. Shapiro, Roshni Kulkarni, Margaret V. Ragni, Hervé Chambost, Johnny Mahlangu, Johannes Oldenburg, Beatrice Nolan, Margareth C. Ozelo, Meredith C. Foster, Annemieke Willemze, Christopher Barnowski, Nisha Jain, Bent Winding, Jennifer Dumont, Stefan Lethagen, Chris Barnes, K. John Pasi
Journal: Blood Advances
Blood Adv (2023) 7 (13): 3049–3057.
https://doi.org/10.1182/bloodadvances.2022009230
Published: 2023
Includes: Supplemental data
Journal Articles

Surgical outcomes in people with hemophilia A taking emicizumab prophylaxis: experience from the HAVEN 1-4 studies

Rebecca Kruse-Jarres, Flora Peyvandi, Johannes Oldenburg, Tiffany Chang, Sammy Chebon, Michelle Y. Doral, Stacy E. Croteau, Thierry Lambert, Christine L. Kempton, Steven W. Pipe, Richard H. Ko, Benjamin Trzaskoma, Christophe Dhalluin, Nives Selak Bienz, Markus Niggli, Michaela Lehle, Ido Paz-Priel, Guy Young, Víctor Jiménez-Yuste
Journal: Blood Advances
Blood Adv (2022) 6 (24): 6140–6150.
https://doi.org/10.1182/bloodadvances.2022007458
Published: 2022
Includes: Supplemental data
Journal Articles

Long-term efficacy and safety of subcutaneous concizumab prophylaxis in hemophilia A and hemophilia A/B with inhibitors

Clinical Trials & Observations
Amy D. Shapiro, Pantep Angchaisuksiri, Jan Astermark, Gary Benson, Giancarlo Castaman, Hermann Eichler, Victor Jiménez-Yuste, Kaan Kavakli, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Allison P. Wheeler, Guy Young, Silva Zupančić-Šalek, Johannes Oldenburg, Pratima Chowdary
Journal: Blood Advances
Blood Adv (2022) 6 (11): 3422–3432.
https://doi.org/10.1182/bloodadvances.2021006403
Published: 2022
Includes: Supplemental data
Journal Articles

Multifaceted pathomolecular mechanism of a VWF large deletion involved in the pathogenesis of severe VWD

Hamideh Yadegari, Muhammad Ahmer Jamil, Jens Müller, Natascha Marquardt, Orla Rawley, Ulrich Budde, Osman El-Maarri, David Lillicrap, Johannes Oldenburg
Journal: Blood Advances
Blood Adv (2022) 6 (3): 1038–1053.
https://doi.org/10.1182/bloodadvances.2021005895
Published: 2022
Includes: Multimedia, Supplemental data
Journal Articles

VKORC1 and VKORC1L1 have distinctly different oral anticoagulant dose-response characteristics and binding sites

Katrin J. Czogalla, Kerstin Liphardt, Klara Höning, Veit Hornung, Arijit Biswas, Matthias Watzka, Johannes Oldenburg
Journal: Blood Advances
Blood Adv (2018) 2 (6): 691–702.
https://doi.org/10.1182/bloodadvances.2017006775
Published: 2018
Includes: Supplemental data